PDF herunterladen
Zentralbl Chir 2006; 131(2): 126-133
DOI: 10.1055/s-2006-921536
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Multimodale Therapie beim Kolonkarzinom?

Multimodal Treatment of Colon Cancer?J. Fahlke1 , C. Schmidt1 , J. Tautenhahn1 , A. Hribaschek1 , P. Stübs1 , H. Lippert1
  • 1Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Otto-von-Guericke-Universität, Magdeburg
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. April 2006 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Nach wie vor stellt die chirurgische Therapie die Basis der Behandlung von Patienten mit einem Kolonkarzinom dar. Multimodale Therapiekonzepte werden derzeit in der adjuvanten Therapie und zunehmend in der systemischen Therapie von Patienten mit primär inoperablen Lebermetastasen zum Erreichen einer sekundären Operabilität nach Vortherapie als therapeutischer Standard angewendet. Im Rahmen der Behandlung des metastasierten Kolonkarzinoms sind interdisziplinäre multimodale Therapiekonzepte derzeit ebenfalls etabliert. Offene Fragen existieren bezüglich der Abfolge der palliativen systemischen Therapien und ihrer Kombination mit lokal ablativen Verfahren.

Abstract

Surgical therapy is still the basis of therapy of patients with colon carcinoma. Multimodal therapeutical concepts are presently applied as a therapeutical standard in the adjuvant therapy and increasingly in the systemic therapy of patients with primarily inoperable metastases of the liver to reach a secondary operability. Interdisciplinary multimodal therapeutical concepts are even accepted within the therapy of metastasized colon carcinomas. There are still unanswered questions regarding sequences of palliative systemic therapies and their combinations with local ablative methods.

Schlüsselwörter

Kolonkarzinom - multimodale Therapie - adjuvante Chemotherapie - palliative Chemotherapie - lokoregionäre Therapie

Key words

colon carcinoma - multimodal therapy - adjuvant chemotherapy - palliative chemotherapy - locoregionary therapy

Literatur

  • 1 Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert H, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial.  J Clin Oncol. 2003;  21 2896-2903
    CrossrefPubMedSuche in Google Scholar
  • 2 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky R L. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.  Ann Oncol. 2002;  13 566-575
    CrossrefPubMedSuche in Google Scholar
  • 3 Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.  Lancet. 2000;  355 1588-1596
    CrossrefPubMedSuche in Google Scholar
  • 4 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Eng J Med. 2004;  351 337-345
    CrossrefPubMedSuche in Google Scholar
  • 5 de Gramont A, Bosset J F, Milan C, Rougier P, Bouche O, Etienne P L, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.  J Clin Oncol. 1997;  15 808-815
    PubMedSuche in Google Scholar
  • 6 de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-2947
    CrossrefPubMedSuche in Google Scholar
  • 7 Deutsche Krebsgesellschaft e. V. .Kurzgefasste Interdisziplinäre Leitlinie 2004. 4. Aufl. W. Zuckschwerdt Verlag, München, Wien, New York 2004; 159-160
  • 8 Douillard J Y, Cunningham D, Roth A D, Navarro M, James R D, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Grnia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.  Lancet. 2000;  355 1041-1047
    CrossrefPubMedSuche in Google Scholar
  • 9 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.  J Clin Oncol. 1998;  16 301-308
    PubMedSuche in Google Scholar
  • 10 Fey M F. Die adjuvante medikamentöse Therapie des Kolon-Karzinoms.  Schweiz Med Wochenschr. 2000;  130 1760-1765
    PubMedSuche in Google Scholar
  • 11 Fong Y, Fortner J, Sun R L, Brennan M F, Baumgart L H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1 001 consecutive cases.  Ann Surg. 1999;  230 309-318
    CrossrefPubMedSuche in Google Scholar
  • 12 Gastinger I, Marusch F. Evidence-based Chirurgie des Kolonkarzinoms.  Zentralbl Chir. 2001;  126 283-288
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset J L, Levi F. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.  Ann Oncol. 1999;  10 663-669
    CrossrefPubMedSuche in Google Scholar
  • 14 Grothey A, Sargent D, Goldberg R M, Schmoll H J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.  J Clin Oncol. 2004;  7 1209-1214
    PubMedSuche in Google Scholar
  • 15 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab (rhuMAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: Results of a randomized phase III trial.  N Engl J Med. 2004;  350 2335-2342
    CrossrefPubMedSuche in Google Scholar
  • 16 International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.  Lancet. 1995;  345 939-944
    CrossrefPubMedSuche in Google Scholar
  • 17 Kabbinavar F, Hurwitz H I, Fehrenbacher L, Meropol N J, Novotny W F, Lieberman G, Griffing S, Bergsland E. Phase II randomized trial comparing bevacizumab plus fluouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.  JCO. 2003;  21 60-65
    CrossrefPubMedSuche in Google Scholar
  • 18 Köckerling F, Reymond M A, Altendorf-Hofmann A, Dworak O, Hohenberger W. Influence of Surgery on metachronous distant metastases and survival in rectal cancer.  J Clin Oncol. 1998;  16 324-329
    PubMedSuche in Google Scholar
  • 19 Köhne C H, Van Cutsem E, Wils J A, Bokemeyer C, El-Sarafi M, Lutz M, Lorenz M, Anak O, Genicot B, Nordlinger B. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986.  Proc Am Soc Clin Oncol. 2003;  22 154
    PubMedSuche in Google Scholar
  • 20 Krebs in Deutschland. 4. überarbeitete aktualisierte Ausgabe. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister, Saarbrücken 2004; 28-32
  • 21 Link K H, Mörschel M, Sagban T A, Appelt V, Holtappels M, Tischbirek K. Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis?.  Chir Gastroenterol. 2004;  20 39-54
    CrossrefPubMedSuche in Google Scholar
  • 22 Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma.  Cancer. 2001;  15 1435-1443
    PubMedSuche in Google Scholar
  • 23 Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.  J Clin Oncol. 1992;  10 896-903
    PubMedSuche in Google Scholar
  • 24 Moertel C G, Fleming T R, Macdonald J S, Haller D G, Laurie J A, Tangen C M, Ungerleider J S, Emerson W A, Tormey D C, Glick J H. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.  Ann Intern Med. 1995;  122 321-326
    CrossrefPubMedSuche in Google Scholar
  • 25 National Comprehensive Cancer Network Guidelines on Treatment of Colon Cancer. available online at www.nccn.org/physician_gls/f_guidelines.html (Accessed 8/10/04)
  • 26 National Comprehensive Cancer Network Guidelines of Treatment of Colon Cancer. www.nccn.org/physician_gls/f_guidelines.html
  • 27 NIH consensus conference . Adjuvant therapy for patients with colon and rectal cancer.  JAMA. 1990;  264 1444
    CrossrefPubMedSuche in Google Scholar
  • 28 Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis.  Ann Surg. 2002;  235 863-871
    CrossrefPubMedSuche in Google Scholar
  • 29 Piedbois P, Michelis S. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2 751 patients.  Proc Am Soc Clin Oncol. 2003;  22 156
    PubMedSuche in Google Scholar
  • 30 Rothenberg M L, Meropol N J, Poplin E A, van Cutsem E, Wadler S. Mortality associatet with irinotecan plus fluorouracil/leucovorin: Summary findings of an independent panel.  J Clin Oncol. 2001;  19 3801-3807
    PubMedSuche in Google Scholar
  • 31 Rougier P, Sahmond T, Nitti D, Curran D, Doci R, de Waek B. for the EORTC GIT Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia and the Japanese Foundation for Cancer Research . Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial.  Lancet. 1998;  351 1677-1681
    CrossrefPubMedSuche in Google Scholar
  • 32 Saini A, Norman A R, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross P J, Oates J. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 month of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.  Br J Cancer. 2003;  88 1859-1865
    PubMedSuche in Google Scholar
  • 33 Saltz L B, Cox J V, Blanke C, Rosen L S, Fehrenbacher L, Moore M J, Maronn J A, Ackland J P, Locker P K, Pirotta N, Elfring G L, Miller L L. Irinotecan plus fluouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.  N Engl J Med. 2000;  343 905-914
    CrossrefPubMedSuche in Google Scholar
  • 34 Saltz L B, Niedzwicki D, Hollis D, Goldberg R M, Hantel A, Thomas P, Fields A LA, Larver G, Mayer R J. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin allone (FL) in stage III colon cancer (intergroup trial CALGB C 89803) (abstract 3500).  Proc Am Soc Clin Oncol. 2004;  23 2455
    PubMedSuche in Google Scholar
  • 35 Scheithauer W, McKendrick J, Begbie S, Borner M, Burns W I, Burris H A, Cassidy J, Jodrell D, Koralewski P, Levine E L, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C. Oral capecitabine as an alternative to i. v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.  Ann Oncol. 2003;  14 1735-1743
    CrossrefPubMedSuche in Google Scholar
  • 36 Schlag P M. Pathomorphologie und Chirurgie-Standards beim kolorektalen Karzinom.  Onkologe. 1998;  4 (Suppl 1) 23-27
    CrossrefPubMedSuche in Google Scholar
  • 37 Scott K W, Grace R H. Detection of lymphe node metastases in colorectal cancer before and after fat clearance.  Br J Surg. 1989;  76 1165-1167
    PubMedSuche in Google Scholar
  • 38 Seufferlein T, Lutz M P, Adler G. Multimodale Therapiekonzepte beim Kolonkarzinom.  Internist. 2003;  44 322-335
    PubMedSuche in Google Scholar
  • 39 Seymour M. Optimizing the use and sequenzing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): The UK MRC FOCUS (CR08) trial.  Ann Onc. 2004;  15 (Suppl 3) iii 2 (5IN)
    PubMedSuche in Google Scholar
  • 40 Stocchi L, Nelson H, Sargant D J, O'Connell M J, Tepper J E, Krook J E, Bart R. Impact of surgical and pathologic variables in rectal cancer: A United States Community and cooperative group report.  J Clin Oncol. 2001;  19 3895-3902
    PubMedSuche in Google Scholar
  • 41 Swiss Group for Clinical Cancer Research (SAKK) . Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer.  Lancet. 1995;  345 349-353
    PubMedSuche in Google Scholar
  • 42 Taylor I, Machin D, Muller M, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.  Br J Surg. 1985;  72 359-363
    PubMedSuche in Google Scholar
  • 43 Willett C G, Goldberg S, Skellito P C, Grossbard M, Clark J, Fung C, Proulx G, Dely M, Kaufmann D S. Does postoperative irradiation play a role in adjuvant therapy of stage T4 colon cancer?.  Cancer J Sci Am. 1999;  514 242-247
    PubMedSuche in Google Scholar
  • 44 Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham D L, Bear H D, Atkins J N, Dimitrov N V, Glass A G, Fisher E R, Fisher B. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.  J Clin Oncol. 1999;  17 3553-3559
    PubMedSuche in Google Scholar

Priv.-Doz. Dr. med. J. Fahlke

Klinik für Allgemein-, Viszeral- und Gefäßchirurgie · Otto-von-Guericke-Universität

Leipziger Str. 44

39120 Magdeburg

Telefon: 03 91/1 56 89

eMail: Joerg.Fahlke@medizin.uni-magdeburg.de